-
KeyBanc Upgrades Catalent On Industry Transformation
Thursday, December 10, 2020 - 10:30am | 245Read More...Catalent Inc (NYSE: CTLT) is a “key component” of the transformation of the health care industry from pharma to biopharma, according to KeyBanc Capital Markets. The Catalent Analyst: Paul Knight upgraded Catalent from Sector Weight to Overweight with a $120 price target. The...
-
Waters Has Limited Upside Potential To Growth Expectations; Janney Steps to The Sidelines
Tuesday, July 17, 2018 - 11:55am | 360Read More...There are better alternatives to Waters Corporation (NYSE: WAT) in the life sciences tools sector from the perspective of acceleration in organic growth, according to an analyst at Janney. The Analyst Paul Knight downgraded Waters Corp from Buy to Neutral and lowered his fair value estimate from $...
-
Janney Initiates CareDx With Buy Rating, $12 Target
Wednesday, February 10, 2016 - 10:24am | 175Read More...Janney Montgomery Scott’s Paul Knight has initiated coverage of CareDx Inc (NASDAQ: CDNA) with a Buy rating and fair value estimate of $12. Unlike most of its peers, Knight believes that CareDx has meaningfully greater upside potential. The company is a leader in the heart transplant...
